[go: up one dir, main page]

PT2945620T - Dadores de nitroxilo com índice terapêutico melhorado - Google Patents

Dadores de nitroxilo com índice terapêutico melhorado

Info

Publication number
PT2945620T
PT2945620T PT147030092T PT14703009T PT2945620T PT 2945620 T PT2945620 T PT 2945620T PT 147030092 T PT147030092 T PT 147030092T PT 14703009 T PT14703009 T PT 14703009T PT 2945620 T PT2945620 T PT 2945620T
Authority
PT
Portugal
Prior art keywords
therapeutic index
improved therapeutic
nitroxyl donors
nitroxyl
donors
Prior art date
Application number
PT147030092T
Other languages
English (en)
Inventor
p toscano John
Jacob Kalish Vincent
Arthur Brookfield Frederick
Martin Courtney Stephen
Marie Frost Lisa
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of PT2945620T publication Critical patent/PT2945620T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT147030092T 2013-01-18 2014-01-17 Dadores de nitroxilo com índice terapêutico melhorado PT2945620T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT2945620T true PT2945620T (pt) 2018-02-21

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
PT147030092T PT2945620T (pt) 2013-01-18 2014-01-17 Dadores de nitroxilo com índice terapêutico melhorado
PT171957590T PT3284463T (pt) 2013-01-18 2014-01-17 Dadores de nitroxilo com índice terapêutico melhorado
PT14703010T PT2945621T (pt) 2013-01-18 2014-01-17 Composições farmacêuticas compreendendo dadores de nitroxilo

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT171957590T PT3284463T (pt) 2013-01-18 2014-01-17 Dadores de nitroxilo com índice terapêutico melhorado
PT14703010T PT2945621T (pt) 2013-01-18 2014-01-17 Composições farmacêuticas compreendendo dadores de nitroxilo

Country Status (29)

Country Link
US (13) US10245249B2 (pt)
EP (5) EP2945620B1 (pt)
JP (5) JP6533159B2 (pt)
KR (2) KR102177899B1 (pt)
CN (4) CN105073105B (pt)
AU (5) AU2014207408C1 (pt)
BR (2) BR112015017251B1 (pt)
CA (2) CA2898443C (pt)
CY (3) CY1120535T1 (pt)
DK (3) DK2945621T3 (pt)
ES (4) ES2705240T3 (pt)
HK (3) HK1216858A1 (pt)
HR (3) HRP20180121T1 (pt)
HU (3) HUE041861T2 (pt)
IL (4) IL239906B (pt)
LT (3) LT2945620T (pt)
MX (2) MX363843B (pt)
NZ (4) NZ709986A (pt)
PL (3) PL2945620T3 (pt)
PT (3) PT2945620T (pt)
RS (3) RS59434B1 (pt)
RU (3) RU2018143994A (pt)
SG (6) SG10201802855TA (pt)
SI (3) SI3284463T1 (pt)
SM (3) SMT201900575T1 (pt)
TR (1) TR201802211T4 (pt)
TW (3) TWI712409B (pt)
WO (2) WO2014113700A1 (pt)
ZA (2) ZA201505090B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200807066T1 (tr) 2006-03-17 2009-11-23 Johns Hopkins University School Of Medicine Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
EP2776402B1 (en) 2011-10-17 2017-07-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
PT2945620T (pt) 2013-01-18 2018-02-21 Cardioxyl Pharmaceuticals Inc Dadores de nitroxilo com índice terapêutico melhorado
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
JP2018526448A (ja) 2015-09-07 2018-09-13 浙江華海薬業股▲フン▼有限公司 一酸化窒素を放出可能なプロドラッグ分子
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
EP3365328A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
ES2878060T3 (es) 2016-07-28 2021-11-18 Univ Johns Hopkins Acidos hidroxámicos O-sustituidos
SG11201906145YA (en) * 2017-01-03 2019-08-27 Cardioxyl Pharmaceuticals Inc Method of administering nitroxyl donating compounds
KR102699958B1 (ko) * 2017-04-18 2024-08-29 장피트 엘라피브라노르와 같은 ppar 작용제 및 아세틸-coa 카르복실라아제 (acc) 저해제를 포함하는 조합
CN116283762A (zh) * 2023-03-28 2023-06-23 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
EP0740649A1 (de) * 1994-01-19 1996-11-06 Byk Nederland BV Nitroxy-gruppen enthaltende benzylaminderivate und ihre verwendung zur behandlung von cardiovasculären erkrankungen sowie erhöhtem augeninnendruck
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
EP1026162A4 (en) 1997-10-24 2001-01-17 Shionogi & Co ANTI-RHUMATISMAL AGENT
EP0930302B1 (en) * 1998-01-16 2003-04-02 F.Hoffmann-La Roche Ag Benzosulfone derivatives
WO1999063385A1 (en) 1998-06-04 1999-12-09 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000006128A1 (fr) 1998-07-28 2000-02-10 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
JP2007522135A (ja) 2004-01-30 2007-08-09 ザ ジョンズ ホプキンス ユニバーシティ ニトロキシル前駆化合物および使用方法
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008543947A (ja) 2005-06-23 2008-12-04 ジョンズ ホプキンス ユニバーシティ チオール感受性の正の変力物質
TR200807066T1 (tr) 2006-03-17 2009-11-23 Johns Hopkins University School Of Medicine Fizyolojik açıdan kullanışlı nıtroksıl donorleri olarak yeni n-htdroksilsülfonamid türevleri
EP2010476A4 (en) 2006-04-13 2011-01-26 Univ Wake Forest Health Sciences NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
CA2699567C (en) 2007-09-26 2018-01-09 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
LT2278975T (lt) 2008-05-07 2016-11-25 Cardioxyl Pharmaceuticals Inc. Nauji nitrozo junginiai kaip nitroksilo donorai, ir jų panaudojimo būdas
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
CA2782248A1 (en) 2009-12-07 2011-06-16 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
CA2782110A1 (en) 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
EP2776402B1 (en) 2011-10-17 2017-07-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
PT2945620T (pt) 2013-01-18 2018-02-21 Cardioxyl Pharmaceuticals Inc Dadores de nitroxilo com índice terapêutico melhorado
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
AU2014207408C1 (en) 2018-09-06
AU2017200147B2 (en) 2018-07-05
ES2882279T3 (es) 2021-12-01
MX2015009269A (es) 2015-10-30
AU2014207408A1 (en) 2015-08-13
CN105142627B (zh) 2019-06-21
US20180235927A1 (en) 2018-08-23
US20220193026A1 (en) 2022-06-23
US11273143B2 (en) 2022-03-15
ES2705240T3 (es) 2019-03-22
CN105142627A (zh) 2015-12-09
JP2017125015A (ja) 2017-07-20
KR20150107853A (ko) 2015-09-23
SG10201913441RA (en) 2020-03-30
US10548872B2 (en) 2020-02-04
US20200163929A1 (en) 2020-05-28
EP2945620A1 (en) 2015-11-25
LT2945620T (lt) 2018-02-12
IL258882A (en) 2018-06-28
LT3284463T (lt) 2019-11-11
NZ748769A (en) 2020-05-29
DK2945621T3 (en) 2019-02-11
SI2945620T1 (en) 2018-01-31
EP3427728B1 (en) 2021-07-07
WO2014113700A9 (en) 2014-10-09
US20140206769A1 (en) 2014-07-24
EP3567031A1 (en) 2019-11-13
US10792273B2 (en) 2020-10-06
SMT201900575T1 (it) 2019-11-13
AU2018203240A1 (en) 2018-05-31
BR112015017251B1 (pt) 2021-10-26
RS58174B1 (sr) 2019-03-29
KR20150108879A (ko) 2015-09-30
HUE046722T2 (hu) 2020-03-30
JP2016505044A (ja) 2016-02-18
HUE036589T2 (hu) 2018-07-30
CA2898443C (en) 2022-05-31
NZ709986A (en) 2020-01-31
IL239906A0 (en) 2015-08-31
MX363843B (es) 2019-04-05
CN105073105B (zh) 2018-02-27
JP6656345B2 (ja) 2020-03-04
HRP20191919T1 (hr) 2020-01-10
CY1121480T1 (el) 2020-05-29
HK1251170B (zh) 2020-04-09
US10213408B2 (en) 2019-02-26
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
MX373176B (es) 2025-03-04
TWI686193B (zh) 2020-03-01
AU2018203240B2 (en) 2019-12-12
AU2014207408A8 (en) 2015-08-27
SMT201900027T1 (it) 2019-02-28
HUE041861T2 (hu) 2019-06-28
SMT201800088T1 (it) 2018-03-08
US11786501B2 (en) 2023-10-17
TW201442702A (zh) 2014-11-16
IL239952A0 (en) 2015-08-31
ZA201505090B (en) 2016-10-26
DK3284463T3 (da) 2019-10-28
RU2018143994A (ru) 2019-01-16
AU2018241168A1 (en) 2018-11-01
AU2017200147A1 (en) 2017-02-02
LT2945621T (lt) 2019-01-10
IL239952B (en) 2018-05-31
WO2014113700A1 (en) 2014-07-24
BR112015017241A8 (pt) 2019-10-29
TW201934120A (zh) 2019-09-01
AU2014207404A1 (en) 2015-08-13
MX2015009276A (es) 2015-10-30
CN110179777A (zh) 2019-08-30
JP6533159B2 (ja) 2019-06-19
TW201446242A (zh) 2014-12-16
JP6801045B2 (ja) 2020-12-16
US20210015784A1 (en) 2021-01-21
PL3284463T3 (pl) 2019-12-31
TWI619491B (zh) 2018-04-01
CN108610312A (zh) 2018-10-02
CY1120535T1 (el) 2019-07-10
JP2019089764A (ja) 2019-06-13
CY1122177T1 (el) 2020-11-25
US20240066002A1 (en) 2024-02-29
RS59434B1 (sr) 2019-11-29
NZ748771A (en) 2019-12-20
HRP20191919T8 (hr) 2021-10-01
BR112015017241B1 (pt) 2021-10-26
US20190224159A1 (en) 2019-07-25
KR102177899B1 (ko) 2020-11-12
BR112015017241A2 (pt) 2017-07-11
US20150175566A1 (en) 2015-06-25
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
SI2945621T1 (sl) 2019-01-31
HRP20182144T1 (hr) 2019-03-08
RU2684916C2 (ru) 2019-04-16
RU2015134583A (ru) 2017-02-22
TR201802211T4 (tr) 2018-03-21
HRP20180121T1 (hr) 2018-02-23
ES2751922T3 (es) 2020-04-02
CA2898445C (en) 2022-05-03
BR112015017251A2 (pt) 2017-07-11
CN105073105A (zh) 2015-11-18
AU2014207408B2 (en) 2018-03-01
US12186301B2 (en) 2025-01-07
EP3427728A1 (en) 2019-01-16
JP6449171B2 (ja) 2019-01-09
RU2676277C2 (ru) 2018-12-27
EP3284463B1 (en) 2019-07-24
EP3284463A1 (en) 2018-02-21
ES2659969T3 (es) 2018-03-20
JP2016510326A (ja) 2016-04-07
HK1216857A1 (zh) 2016-12-09
DK2945620T3 (en) 2018-02-05
IL259233B (en) 2019-10-31
US9968584B2 (en) 2018-05-15
US9586896B2 (en) 2017-03-07
PL2945620T3 (pl) 2018-03-30
SG10201802862WA (en) 2018-05-30
IL239906B (en) 2018-05-31
EP2945620B1 (en) 2017-11-22
AU2018241168B2 (en) 2020-04-02
CA2898445A1 (en) 2014-07-24
HK1216858A1 (zh) 2016-12-09
TWI712409B (zh) 2020-12-11
JP2019172682A (ja) 2019-10-10
KR102277165B1 (ko) 2021-07-14
SG10201913286PA (en) 2020-02-27
PT2945621T (pt) 2019-01-21
US20170151210A1 (en) 2017-06-01
ZA201604798B (en) 2018-01-31
SG10201802855TA (en) 2018-05-30
US20190133990A1 (en) 2019-05-09
US10245249B2 (en) 2019-04-02
NZ709985A (en) 2020-05-29
WO2014113696A1 (en) 2014-07-24
US10517847B2 (en) 2019-12-31
IL259233A (en) 2018-07-31
US9156804B2 (en) 2015-10-13
CA2898443A1 (en) 2014-07-24
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
AU2014207404B2 (en) 2017-10-19
PL2945621T3 (pl) 2019-05-31
CN110179777B (zh) 2022-07-15
BR112015017251A8 (pt) 2019-10-29
SG11201505567RA (en) 2015-09-29
SI3284463T1 (sl) 2019-12-31
US8987326B2 (en) 2015-03-24
PT3284463T (pt) 2019-10-30
JP6311038B2 (ja) 2018-04-11

Similar Documents

Publication Publication Date Title
HRP20191919T8 (hr) Donori nitroksila sa poboljšanim terapijskim indeksom
HK1223402A1 (zh) 免疫溶瘤療法
HK1220929A1 (zh) 自動注射器
HK1220214A1 (zh) 變體
HK1218522A1 (zh) 自動注射器
HK1218521A1 (zh) 自動注射器
HK1218401A1 (zh) 自動注射器
ZA201506252B (en) Syringe
HK1218523A1 (zh) 自動注射器
GB201309652D0 (en) Aa centrifuge
HK1218400A1 (zh) 自動注射器
EP2914254A4 (en) COMBINATION THERAPIES
GB201300538D0 (en) Polycarbonates
EP2978473A4 (en) AUTOMATIC RETRACTABLE SYRINGE
PL3002315T3 (pl) Kompozycja żywicy poliwęglanowej
GB2510813B (en) Letter-plate with fluid-damped hinges
UA25853S (uk) Графин із закупорювальним засобом
GB201300539D0 (en) Polycarbonates